Healthcare provider profile · identity verified

Stephen B Tilley, MD

Family Practice · LITTLE ROCK, AR · NPI 1205833738

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	481	136
Amlodipine Besylate	Amlodipine Besylate	475	137
Levothyroxine Sodium	Levothyroxine Sodium	372	98
Lisinopril	Lisinopril	296	89
Metoprolol Succinate	Metoprolol Succinate	278	84
Rosuvastatin Calcium	Rosuvastatin Calcium	244	78
Tamsulosin Hcl	Tamsulosin Hcl	231	70
Pantoprazole Sodium	Pantoprazole Sodium	226	60
Metformin Hcl	Metformin Hcl	223	63
Omeprazole	Omeprazole	190	58
Azithromycin	Azithromycin	174	139
Bupropion Xl	Bupropion Hcl	152	44
Furosemide	Furosemide	142	39
Trazodone Hcl	Trazodone Hcl	141	49
Gabapentin	Gabapentin	139	48
Losartan Potassium	Losartan Potassium	136	46
Olmesartan Medoxomil	Olmesartan Medoxomil	130	35
Allopurinol	Allopurinol	127	36
Eliquis	Apixaban	112	22
Albuterol Sulfate Hfa	Albuterol Sulfate	105	41
Duloxetine Hcl	Duloxetine Hcl	105	32
Tizanidine Hcl	Tizanidine Hcl	103	54
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	96	29
Clonidine Hcl	Clonidine Hcl	95	25
Diclofenac Sodium	Diclofenac Sodium	94	38
Hydrochlorothiazide	Hydrochlorothiazide	93	29
Escitalopram Oxalate	Escitalopram Oxalate	92	35
Atenolol	Atenolol	90	30
Meloxicam	Meloxicam	88	36
Prednisone	Prednisone	88	62
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	85	31
Simvastatin	Simvastatin	74	16
Amoxicillin	Amoxicillin	72	58
Metoprolol Tartrate	Metoprolol Tartrate	69	23
Clonazepam	Clonazepam	68	17
Buspirone Hcl	Buspirone Hcl	66	27
Pioglitazone Hcl	Pioglitazone Hcl	60	17
Valacyclovir	Valacyclovir Hcl	55	25
Clopidogrel	Clopidogrel Bisulfate	52	15
Levofloxacin	Levofloxacin	50	40
Montelukast Sodium	Montelukast Sodium	50	17
Methylprednisolone	Methylprednisolone	49	44
Mounjaro	Tirzepatide	48	suppressed
Carvedilol	Carvedilol	47	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	47	16
Spironolactone	Spironolactone	47	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	46	38
Fluoxetine Hcl	Fluoxetine Hcl	46	16
Cephalexin	Cephalexin	43	27
Doxycycline Hyclate	Doxycycline Hyclate	43	29
Glimepiride	Glimepiride	43	suppressed
Ipratropium Bromide	Ipratropium Bromide	43	18
Pravastatin Sodium	Pravastatin Sodium	43	13
Sertraline Hcl	Sertraline Hcl	42	15
Acetaminophen-Codeine	Acetaminophen With Codeine	41	30
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	40	22
Potassium Chloride	Potassium Chloride	40	17
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	39	suppressed
Finasteride	Finasteride	39	14
Ondansetron Odt	Ondansetron	37	24
Citalopram Hbr	Citalopram Hydrobromide	36	12
Acyclovir	Acyclovir	35	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	33	suppressed
Cefdinir	Cefdinir	32	21
Estradiol	Estradiol	31	11
Oxybutynin Chloride Er	Oxybutynin Chloride	31	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	31	suppressed
Nebivolol Hcl	Nebivolol Hcl	30	suppressed
Verapamil Er	Verapamil Hcl	30	suppressed
Jardiance	Empagliflozin	27	suppressed
Synthroid	Levothyroxine Sodium	27	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	26	12
Doxepin Hcl	Doxepin Hcl	26	suppressed
Ibuprofen	Ibuprofen	26	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	26	13
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	25	22
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	24	12
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	17
Topiramate	Topiramate	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Alprazolam	Alprazolam	19	suppressed
Fluconazole	Fluconazole	19	11
Betamethasone Dipropionate	Betamethasone Dipropionate	18	13
Celecoxib	Celecoxib	17	suppressed
Mupirocin	Mupirocin	17	11
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Ramipril	Ramipril	16	suppressed
Temazepam	Temazepam	16	suppressed
Naproxen	Naproxen	15	suppressed
Tramadol Hcl	Tramadol Hcl	14	11
Donepezil Hcl	Donepezil Hcl	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Fluticasone Propionate	Fluticasone Propionate	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	12
Triazolam	Triazolam	13	11
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Ozempic	Semaglutide	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Colchicine	Colchicine	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Premarin	Estrogens, Conjugated	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error